SCHEMBL1049635

SCHEMBL1049635

O=c1[nH]ccc2c(-c3ccccc3)cnc(Nc3ccccc3)c12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ZAP70 P43403 3/20 0.53
TTBK1 Q5TCY1 2/20 0.46
TTBK2 Q6IQ55 2/20 0.46
JAK2 O60674 5/20 0.41
AURKB Q96GD4 3/20 0.41
MAP4K4 O95819 2/20 0.41
PRKACA P17612 2/20 0.41
CLK4 Q9HAZ1 2/20 0.41
IKBKB O14920 1/20 0.41
CHUK O15111 1/20 0.41
DAPK3 O43293 1/20 0.41
PRKD3 O94806 1/20 0.41
PAK4 O96013 1/20 0.41
CSF1R P07333 1/20 0.41
RET P07949 1/20 0.41
IGF1R P08069 1/20 0.41
FGFR1 P11362 1/20 0.41
FLT1 P17948 1/20 0.41
LTK P29376 1/20 0.41
GRK5 P34947 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1048999 0.93 ZAP70 (0.49) ZAP70TTBK1TTBK2JAK2AURKB
SCHEMBL1043299 0.92 JAK2 (0.49) ZAP70TTBK1TTBK2JAK2FGFR1
SCHEMBL1048942 0.92 ZAP70 (0.48) ZAP70TTBK1TTBK2JAK2FGFR1
SCHEMBL27806170 0.92 ZAP70 (0.51) ZAP70TTBK1TTBK2JAK2AURKB
SCHEMBL1049397 0.91 NUDT1 (0.48) ZAP70TTBK1TTBK2JAK2AURKB
SCHEMBL1048512 0.90 ZAP70 (0.47) ZAP70TTBK1TTBK2JAK2AURKB
SCHEMBL1049370 0.89 ZAP70 (0.46) ZAP70TTBK1TTBK2JAK2IGF1R
SCHEMBL1047746 0.89 ZAP70 (0.46) ZAP70TTBK1TTBK2JAK2AURKB
SCHEMBL1045523 0.89 JAK2 (0.49) ZAP70TTBK1TTBK2JAK2MAP4K4
SCHEMBL1049280 0.89 MAPT (0.49) ZAP70TTBK1TTBK2FGFR1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US claimed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US claimed
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US disclosed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US disclosed
EP-2238137-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-10-13 EP disclosed
WO-2009097287-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FYN, SYK, RET ZAP70 4/4885TTBK1 488/4885TTBK2 479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.